Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002166 · ClinicalTrials.gov registry record · Phase 3
An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00002166: Completed Phase 3 study, sponsored by Boehringer Ingelheim.
NCT00002166 is a Phase 3 study that has completed, run by Boehringer Ingelheim. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002166, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
To provide access to Viramune and to evaluate the tolerance and safety of Viramune in patients with progressive, symptomatic HIV disease who failed or are intolerant to currently approved treatment for HIV-1 infection and who are unable to participate in another Viramune controlled clinical trial and have a compelling need for anti-HIV treatment.
Interventions
- DRUG Nevirapine
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 3 |
What the finished NCT00002166 record still lists
NCT00002166 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Nevirapine is the first listed.
NCT00002166 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002166 about?
NCT00002166 is a clinical study titled "An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease". To provide access to Viramune and to evaluate the tolerance and safety of Viramune in patients with progressive, symptomatic HIV disease who failed or are intolerant to currently approved treatment for HIV-1 infection and who are unable to participate in another Viramune controlled clinical trial an...
What is the current status of trial NCT00002166?
This trial is currently completed. It is a Phase 3 study.
What interventions are being tested in trial NCT00002166?
The interventions under investigation include: Nevirapine (DRUG).
Who is sponsoring clinical trial NCT00002166?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.